Cosentyx (secukinumab) - Novartis
CMAB015 (secukinumab biosimilar) - Mabpharm Limited
Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers (clinicaltrials.gov) - Oct 22, 2026 - P1 | N=114 | Completed | Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd | Active, not recruiting ➔ Completed 
Trial completion • Dermatology • Immunology • Psoriasis
http://clinicaltrials.gov/ct2/show/NCT07254325
 
Oct 22, 2026
 
Prev Next